Evidence Synthesis
NATCOPHARM's Gross Margin accelerated to 82.64%, up from 18.96%.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 8 Sept 2026, 20:32
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
NATCOPHARM's Gross Margin accelerated to 82.64%, up from 18.96%.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 82.64 % | 18.96 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 18.96 % | 32.84 | ▼ |
| REVENUE_GROWTH_YOY | -44.7 % | -57 | ▲ |
| EPS_ACTUAL | 28.94 INR | 8.46 | ▲ |
| EPS_SURPRISE_PERCENT | 0.179 % | -0.024 | ▲ |
| PRICE_CHANGE_PERCENT | -1.497 % | — | - |
| DAILY_VOLUME | 3,01,905 shares | 5,40,334 | ▼ |
| CLOSE_PRICE | 825.75 INR | 838.3 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.18 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 2 count | 3 | ▼ |
| TARGET_PRICE_PREMIUM | 21.64 % | — | - |